Preview

Медицинский Совет

Расширенный поиск

Ведение пациентов с болезнью Альцгеймера

https://doi.org/10.21518/2079-701X-2018-1-6-12

Полный текст:

Аннотация

Представлен обзор литературных данных по ведению пациентов с болезнью Альцгеймера (БА). Психосоциальные и поведенческие направления составляют основу ведения пациента с БА и должны использоваться как можно раньше и оставаться на протяжении всей оставшейся жизни. Ингибиторы центральной ацетилхолинэстеразы (донепезил, галантамин, ривастигмин) и мемантин способны улучшить когнитивные функции. Профилактика инсульта расценивается как наиболее эффективное средство снижения риска развития БА и прогрессирования ее симптомов. Постепенная нормализация артериального давления у пациентов с артериальной гипертензией уменьшает риск возникновения различных типов деменций, включая БА. Употребление в большом количестве свежих фруктов или овощей, средиземноморская диета, регулярные физические нагрузки и умственная активность сочетаются со снижением частоты развития БА. Обсуждаются особенности ведения пациентов с БА в нашей стране, применение Церебролизина и методы вакцинации.

 

Об авторах

В. А. Парфенов
Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский университет)
Россия
д.м.н., профессор


А. Р. Кабаева
Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский университет)
Россия


Список литературы

1. Cerebrovascular disease, cognitive impairment and dementia. Cerebrovascular disease and dementia. 2nd ed. Edited by O’Brien J, Ames D, Gustafson L, et al. London, N.Y.: Martin Dunitz; 2004.

2. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and meta-analysis. Alzheimers Dement, 2013, 9: 63–75.

3. World Health Organization, Alzheimer’s Disease International. Dementia: a public health priority. [Internet] Geneva: World Health Organization, 2012.

4. Reiman EM, Langbaum JB, Tario PN. Alzheimer’s Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med, 2010, 4(1): 3–14.

5. Chertkow H, Feldman HH, Jacova C, et al. Definitions of dementia and predementia states in Alzheimer’s disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimers Res Ther, 2013, 5(Suppl 1): S2.

6. Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA, 2003, 290: 2015-2022.

7. Kales H, Gitlin L, Lyketsos C. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc, 2014, 62: 762-769.

8. Carretti B, Borella E, Fostinelli S, et al. Benefits of training working memory in amnestic mild cognitive impairment: specific and transfer effects. Int Psychogeriatr, 2013, 25(4): 617-26.

9. Gates N, Valenzuela M. Cognitive exercise and its role in cognitive function in older adults. Curr Psychiatry Rep, 2010, 12: 20-27.

10. Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev, 2013, 6: CD003260.

11. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev, 2006, 1: CD005593.

12. Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med, 2008, 148: 370-378.

13. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry, 1999, 14: 135–146.

14. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med, 2003, 348: 1333–1341.

15. van Dyck CH, Schmitt FA, Olin JT, Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry, 2006, 14: 428–437.

16. Grossberg GT, Pejovic V, Miller ML, Graham SM. Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord, 2009, 27: 164–172.

17. Ishikawa I, Shinno H, Ando N, et al. The effect of memantine on sleep architecture and psychiatric symptoms in patients with Alzheimer’s disease. Acta Neuropsychiatrica, 2016, 28(3): 157-164.

18. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 2005, 294: 1934-1943.

19. Ballard C, Hanney ML, Theodoulou M. et al. The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomized placebo-controlled trial. Lancet Neurol, 2009, 8: 151–157.

20. Kales H, Kim H, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry, 2012, 169: 71-79.

21. Reus V, Fochtmann L, Eyler A, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry, 2016, 162: 1996-2021.

22. Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: Week-24 outcomes. Am J Geriatr Psychiatry, 2010, 18: 332–340.

23. Colcombe S, Kramer AF. Fitness effects on the cognitive function of older adults: a meta-analytic study. Psychological Science, 2003, 14: 125–130.

24. Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Annals of Internal Medicine, 2006, 144: 73–81.

25. Barnes DE, Blackwell T, Stone KL et al. Cognition in older women: the importance of daytime movement. Journal of the American Geriatrics Society, 2008, 56:1658–1664.

26. Beckett MW, Ardern CI, Rotondi MA. A meta-analysis of prospective studies on the role of physical activity and the prevention of Alzheimer’s disease in older adults. BMC Geriatr, 2015, 15: 9.

27. Del Parigi A, Panza F, Capurso C, Solfrizzi V. Nutritional factors, cognitive decline, and dementia. Brain Research Bulletin, 2006, 69: 1–19.

28. Morris MC, Evans DA, Tangney CC, et al. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology, 2006, 67: 1370–1376.

29. Scarmeas N, Stern Y, Mayeux R, et al. Mediterranean diet and mild cognitive impairment. Arch Neurol, 2009, 66: 216–225.

30. Larrieu S, Letenneur L, Helmer C, et al. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr Health Aging, 2004, 8: 150-154.

31. Wilson RS, Scherr PA, Schneider JA, et al. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology, 2007, 69: 1911–1920.

32. Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М.: МИА, 2012, 288 с.

33. Patterson C, Feightner JW, Garcia A, et al. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Canadian Medical Association Journal, 2008, 178: 548–556.

34. De Craen AJM, Gussekloo J, Vrijsen B, et al. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol, 2005, 161: 114-120.

35. Wang J, Tan L, Wang HF, et al. Anti-inflammatory drugs and risk of Alzheimer’s disease: an updated systematic review and meta-analysis. J Alzheimers Dis, 2015, 44(2): 385-96.

36. ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology, 2007, 68: 1800-1808.

37. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA, 2002, 288: 872–881.

38. Shumaker SA, Legault C, Kuller L, et al. Women’s Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA, 2004, 291: 2947–2958.

39. Boothby LA, Doering PL. Vitamin C and vitamin E for Alzheimer’s disease. Ann Pharmacother, 2005, 39: 2073-2080.

40. Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet, 2007, 369: 208–216.

41. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA, 2008, 300: 2253-2262.

42. Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol, 2012, 11: 851-859.

43. von Gunten A, Schlaefke S, Überla K. Efficacy of Ginkgo biloba extract EGb 761® in dementia with behavioural and psychological symptoms: A systematic review. World J Biol Psychiatry, 2016, 17(8): 622-633.

44. Парфенов В.А., Захаров В.В., Преображенская И.С. Когнитивные расстройства. М.: Ремедиум, 2014. 224 с.

45. Неверовский Д.В., Случевская С.Ф., Парфенов В.А. Дифференциальный диагноз дисциркуляторной энцефалопатии в амбулаторной практике. Неврология, нейропсихиатрия и психосоматика, 2013, 5(2): 38-42.

46. Alvarez XA, Fuentes P. Cerebrolysin in Alzheimer’s disease. Drugs Today (Barc), 2011, 47: 487-513.

47. Wei ZH, He QB, Wang H, et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease. J Neural Transm, 2007, 114(5): 629-34.

48. Plosker GL, Gautheir S. Cerebrolysin: a review of its use in dementia. Drugs Aging, 2009, 26(11): 893-915.

49. Gauthier S, Proano JV, Jia J, et al. Cerebrolysin in Mild-to-Moderate Alzheimer’s Disease: A Meta-Analysis of Randomized Controlled Clinical Trials. Dement Geriatr Cogn Disord, 2015, 39: 340-55.

50. Panza F, Solfrizzi V, Frisardi V, et al. Disease modifying approach to the treatment of Alzheimer’s disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators. Drugs Aging, 2009, 26(7): 537-555.

51. Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, 2016, 537(7618): 50-6.


Просмотров: 234


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)